FDA approves prostate cancer and Crohn’s disease therapies as judge rejects effort to block Lilly weight‑loss ads

The U.S. Food and Drug Administration announced approvals for new treatments targeting prostate cancer and Crohn’s disease. The decisions expand therapeutic options for patients with these conditions.

A federal judge declined to issue an injunction that would have stopped advertising for Lilly’s weight‑loss medication, allowing the company to continue its marketing campaign.

Separately, FDA officials and industry experts met at The MedTech Conference to discuss guidance on de novo classification requests and upcoming changes under the Medical Device User Fee Amendments (MDUFA VI) program, offering insights for medical device developers.